findmyKOL
Clinical trialNCT02967133TerminatedPhase 2Interventional

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

SponsorAlliance Foundation Trials, LLC.Enrollment7Non Small Cell Lung Cancer RecurrentNon-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small-Cell Lung Cancer MetastaticNonsmall Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression for a subset of NSCLC patients receiving nivolumab is a specific area of clinical need.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • St. Elizabeth'S Healthcare

    Edgewood, Kentucky, United States

  • Metro Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota, United States

  • Missouri Baptist Medical Center

    St Louis, Missouri, United States

  • Nebraska Methodist Hospital

    Omaha, Nebraska, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Nivolumab →Paclitaxel →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2016
Primary completion
31 Jan 2018
Completion
31 Jan 2018
Last update posted
8 Sept 2022
Registered enrollment
7
Registry id
NCT02967133
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.